Symposium Speaker: Patrick Raber, PhD

Patrick Raber, PhD

Dr. Patrick Raber is a scientific liaison with Adaptive Biotechnologies, a biotechnology company based in Seattle, Washington that specializes in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Previous to his position at Adaptive, Patrick earned his PhD in the Department of Microbiology, Immunology, at Parasitology at LSU Health Sciences Center New Orleans. Based in Atlanta, Georgia, Patrick serves as scientific expert for applications of Adaptive’s immunosequencing platform including oncology, immunotherapy, transplantation, infectious diseases, and autoimmunity.  Patrick also assists investigators interested in incorporating Adaptive’s technology into clinical trials and research protocols.  

PUBLICATIONS ON ADAPTIVE BIOTECHNOLOGIES IMMUNOSEQ

DeWitt WS, et al. A Public Database of Memory and Naive B-Cell Receptor Sequences. PLoS One 2016. PMID:27513338

Howie B, et al. High-throughput pairing of T-cell receptor alpha and beta sequences. Sci Transl Med 2016. PMID:26290413

Tweets by Adaptive Biotechnologies

This #bloodcancerawareness month, we’re honored to introduce Karen, a multiple myeloma survivor who reflects on her cancer journey and the critical role of minimal residual disease (MRD) testing.

Adaptive is committed to recognizing scientists pursuing exciting research in immunology. Hear from our latest immunoSEQ® YIA and WISE award winners in our latest blog post. adaptivebio.tech/zv8 For Research Use Only. Not for use in diagnostic procedures.

test Twitter Media - Adaptive is committed to recognizing scientists pursuing exciting research in immunology. Hear from our latest immunoSEQ® YIA and WISE award winners in our latest blog post. https://t.co/rocpU3bRmO 

For Research Use Only. Not for use in diagnostic procedures. https://t.co/ULSoKkT40t

Attending the 7th @CAR_TCell Summit in Boston, MA next week? Join Sr. Director @ErikYusko for his Discovery Track presentation on, “Adaptive’s TCR Discovery Platform & Immune Monitoring of CAR/TCR Products.” Wednesday, September 21st at 2:30PM ET. adaptivebio.tech/df8

test Twitter Media - Attending the 7th @CAR_TCell Summit in Boston, MA next week? Join Sr. Director @ErikYusko for his Discovery Track presentation on, “Adaptive’s TCR Discovery Platform & Immune Monitoring of CAR/TCR Products.” Wednesday, September 21st at 2:30PM ET. https://t.co/kOXjpGIXhG https://t.co/Gkktawzavn

Congrats to Katie Lowe, recipient of our 2022 WISE Award! Katie's research aims to characterize the TCR diversity in lymphoid infiltrated synovial tissue (LIST) patients with rheumatoid arthritis. adaptivebio.tech/n2p For Research Use Only. Not for use in diagnostic procedures

test Twitter Media - Congrats to Katie Lowe, recipient of our 2022 WISE Award! Katie's research aims to characterize the TCR diversity in lymphoid infiltrated synovial tissue (LIST) patients with rheumatoid arthritis. https://t.co/jhfX4dLG15
For Research Use Only. Not for use in diagnostic procedures https://t.co/g9o2hpVfJ9

The financing with OrbiMed will provide flexibility to invest in growth initiatives in both MRD and Immune Medicine businesses. Press release: adaptivebio.tech/mst

test Twitter Media - The financing with OrbiMed will provide flexibility to invest in growth initiatives in both MRD and Immune Medicine businesses. Press release: https://t.co/S1NGa8Wjv9 https://t.co/eSTtpjeWnm

This #bloodcancerawareness month, SVP Susan Bobulsky discusses Adaptive’s “patient first” culture and recent efforts with @ACCCbuzz and @NCODAorg to share minimal residual disease (MRD) education with community doctors treating blood cancers. Blog post: adaptivebio.tech/x5y

test Twitter Media - This #bloodcancerawareness month, SVP Susan Bobulsky discusses Adaptive’s “patient first” culture and recent efforts with @ACCCbuzz and @NCODAorg to share minimal residual disease (MRD) education with community doctors treating blood cancers. Blog post: https://t.co/fCILNaTrnG https://t.co/5ZXH8tkXD5

Attending the @DPC_Summit next week? On Wednesday, September 7th at 11:20am ET, join Katie Boland, DVM, PhD for her presentation, “Turning large scale immune repertoire data into insights in infectious disease.” More info: adaptivebio.tech/di7

test Twitter Media - Attending the @DPC_Summit next week? On Wednesday, September 7th at 11:20am ET, join Katie Boland, DVM, PhD for her presentation, “Turning large scale immune repertoire data into insights in infectious disease.” More info: https://t.co/cueaqsuJy7 https://t.co/uSyHe4DbiB

Join Adaptive’s Mia Barnes, Sr. Medical Science Liaison, at this year’s @DPC_Summit for a talk on, "T-cell immune response: vaccine development and COVID-19 variants.” Wednesday, September 7th at 12:20pm ET. Register here: adaptivebio.tech/di7

test Twitter Media - Join Adaptive’s Mia Barnes, Sr. Medical Science Liaison, at this year’s @DPC_Summit for a talk on, "T-cell immune response: vaccine development and COVID-19 variants.” Wednesday, September 7th at 12:20pm ET. Register here: https://t.co/cueaqsuJy7 https://t.co/kcoPgkjCqn

Thanks, @Nasdaq! We are so proud of our team and all participants who made this 10th anniversary of #Obliteride a success with raising funds to support lifesaving research.

test Twitter Media - Thanks, @Nasdaq! We are so proud of our team and all participants who made this 10th anniversary of #Obliteride a success with raising funds to support lifesaving research. https://t.co/6F0JArDdWm

Congrats to Claire Guinier, our Q2 2022 Young Investigator Award winner! Her research aims to understand the role of T cells in CAV, the leading cause of mortality following heart transplantation. adaptivebio.tech/inl For Research Use Only. Not for use in diagnostic procedures

test Twitter Media - Congrats to Claire Guinier, our Q2 2022 Young Investigator Award winner! Her research aims to understand the role of T cells in CAV, the leading cause of mortality following heart transplantation. https://t.co/JEBydTYRmx
For Research Use Only. Not for use in diagnostic procedures https://t.co/ptCr4CgG1j

Sr. Medical Director Allison Jacob discusses the recent @bloodcancerjnl survey by @bdermanmd and the shifting clinician attitudes on MRD-guided decision making in multiple myeloma. Read the blog: adaptivebio.tech/ag4

test Twitter Media - Sr. Medical Director Allison Jacob discusses the recent @bloodcancerjnl survey by @bdermanmd and the shifting clinician attitudes on MRD-guided decision making in multiple myeloma. Read the blog: https://t.co/anSjl2WSjK https://t.co/Zyx3cCZ679

Congrats to Girija Goyal, PhD, winner of our 2022 WISE Award! Learn more about her research into the use of LN chips to replicate and study human immune response to infection & vaccination at adaptivebio.tech/ywf. For research Use Only. Not for use in diagnostic procedures.

test Twitter Media - Congrats to Girija Goyal, PhD, winner of our 2022 WISE Award! Learn more about her research into the use of LN chips to replicate and study human immune response to infection & vaccination at https://t.co/AccXG0Nbw4. 

For research Use Only. Not for use in diagnostic procedures. https://t.co/pZwSgF3T8N

#Obliteride is an inspiring event and we're so proud of Team Adaptive and all the participants who took part in the cause to raise funds for life-saving cancer research. A big shout-out to Adaptive’s @bryan_howie for biking 4K miles and Team Adaptive for logging over 9K miles!

test Twitter Media - #Obliteride is an inspiring event and we're so proud of Team Adaptive and all the participants who took part in the cause to raise funds for life-saving cancer research. A big shout-out to Adaptive’s @bryan_howie for biking 4K miles and Team Adaptive for logging over 9K miles! https://t.co/qqzMQ4Sknk
test Twitter Media - #Obliteride is an inspiring event and we're so proud of Team Adaptive and all the participants who took part in the cause to raise funds for life-saving cancer research. A big shout-out to Adaptive’s @bryan_howie for biking 4K miles and Team Adaptive for logging over 9K miles! https://t.co/qqzMQ4Sknk
test Twitter Media - #Obliteride is an inspiring event and we're so proud of Team Adaptive and all the participants who took part in the cause to raise funds for life-saving cancer research. A big shout-out to Adaptive’s @bryan_howie for biking 4K miles and Team Adaptive for logging over 9K miles! https://t.co/qqzMQ4Sknk
test Twitter Media - #Obliteride is an inspiring event and we're so proud of Team Adaptive and all the participants who took part in the cause to raise funds for life-saving cancer research. A big shout-out to Adaptive’s @bryan_howie for biking 4K miles and Team Adaptive for logging over 9K miles! https://t.co/qqzMQ4Sknk

The Sustainability @ Adaptive Employee Resource Group kicked off the first official harvest of the Adaptive rooftop garden a few weeks ago and made a donation to the @udistfoodbank! We're looking forward to the next harvest!

test Twitter Media - The Sustainability @ Adaptive Employee Resource Group kicked off the first official harvest of the Adaptive rooftop garden a few weeks ago and made a donation to the @udistfoodbank! We're looking forward to the next harvest! https://t.co/jeSQJiovSL
test Twitter Media - The Sustainability @ Adaptive Employee Resource Group kicked off the first official harvest of the Adaptive rooftop garden a few weeks ago and made a donation to the @udistfoodbank! We're looking forward to the next harvest! https://t.co/jeSQJiovSL
test Twitter Media - The Sustainability @ Adaptive Employee Resource Group kicked off the first official harvest of the Adaptive rooftop garden a few weeks ago and made a donation to the @udistfoodbank! We're looking forward to the next harvest! https://t.co/jeSQJiovSL
test Twitter Media - The Sustainability @ Adaptive Employee Resource Group kicked off the first official harvest of the Adaptive rooftop garden a few weeks ago and made a donation to the @udistfoodbank! We're looking forward to the next harvest! https://t.co/jeSQJiovSL

MRD Chief Commercial Officer Nitin Sood discusses being on the patient’s side of the cancer journey and the profound influence it has in shaping his career path. adaptivebio.tech/k9a

test Twitter Media - MRD Chief Commercial Officer Nitin Sood discusses being on the patient’s side of the cancer journey and the profound influence it has in shaping his career path. https://t.co/deDK5awMOP https://t.co/8hwP5Lnuhk

Happy National Intern Day! We’re delighted to work with all our amazing 2022 interns. Here are a few members of the cohort, who are joining us from locations and institutions across the country. #nationalinternday

test Twitter Media - Happy National Intern Day! We’re delighted to work with all our amazing 2022 interns. Here are a few members of the cohort, who are joining us from locations and institutions across the country. #nationalinternday https://t.co/wPWTkI895b

.@clonoSEQ is the first and only MRD assay to receive Medicare coverage in DLBCL. Press release: adaptivebio.tech/gdp clonoSEQ is FDA-cleared to assess MRD in patients with CLL, MM, or B-ALL. For important info. incl. sample types & test limitations: rb.gy/8tju9y

test Twitter Media - .@clonoSEQ is the first and only MRD assay to receive Medicare coverage in DLBCL. Press release: https://t.co/yXCV9MWbd4

clonoSEQ is FDA-cleared to assess MRD in patients with CLL, MM, or B-ALL. For important info. incl. sample types & test limitations: https://t.co/FihIM4XpIK https://t.co/9aeIH0iJbO

Immune Medicine has the power to transform how we detect and treat disease. Learn how Adaptive is harnessing the adaptive immune system to unleash its power as a natural diagnostic and therapeutic tool to propel a paradigm shift in medicine. adaptivebio.tech/svt

We’re proud to be a sponsor of the 4th Cell Therapies and Immunotherapy Conference! Join Adaptive’s Amy Gilbert and Amritha Lewis as they discuss advancements in cell-based immunotherapies. More info: adaptivebio.tech/8f2 #SBE #CellTherapies22

test Twitter Media - We’re proud to be a sponsor of the 4th Cell Therapies and Immunotherapy Conference! Join Adaptive’s Amy Gilbert and Amritha Lewis as they discuss advancements in cell-based immunotherapies.  More info: https://t.co/vjlZQOXUZV  

#SBE #CellTherapies22 https://t.co/xOQ3jfiWGE

If you have turned on the news recently, you may have heard of talk about antibodies, antigens and T cells. In this short primer, we break down the cast of characters in your adaptive immune system.

Adaptive Biotechnologies Website